Purecraft LLC – FDA Warning Letter, Jan 6, 2023
On January 10, 2023, the FDA and FTC issued a Warning Letter to Purecraft CBD after reviewing their website (purecraftcbd.com) and social media (Facebook, Instagram) on December 14, 2022, and January 6, 2023. The letter states that Purecraft CBD offers cannabidiol (CBD) products for sale in the U.S. that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19.
These products are cited as unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 of the FD&C Act (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) of the FD&C Act (21 U.S.C. § 331(a) and (d)). The letter provides examples of claims from Purecraft CBD's website, such as "COVID Prevention & CBD," "therapeutic doses of CBD do have a protective effect against COVID," and "CBD has been shown to decrease the severity of COVID."
Purecraft CBD is required to take immediate action to cease the sale of all unapproved and unauthorized products
ID · 27421e76-79b7-4f6a-948c-af234feb2904
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.